| Title: | Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial |
Authors: | Grosicki, S.
Simonova, M.
Spicka, I.
Pour, L.
Kriachok, I.
Gavriatopoulou, M.
Pylypenko, H.
Auner, H.W.
Leleu, X.
Doronin, V.
Usenko, G.
Bahlis, N.J.
Hajek, R.
Benjamin, R.
Dolai, T.K.
Sinha, D.K.
Venner, C.P.
Garg, M.
Gironella, M.
Jurczyszyn, A.
Robak, P.
Galli, M.
Wallington-Gates, Craig Thomas
Radinoff, A.
Salogub, G.
Stevens, D.A.
Basu, S.
Liberati, A.M.
Quach, H.
Goranova-Marinova, V.S.
Bila, J.
Katodritou, E.
Oliynyk, H.
Korenkova, S.
Kumar, J.
Jagannath, S.
Moreau, P.
Levy, M.
White, D.
Gatt, M.E.
Facon, T.
Mateos, M.V.
Cavo, M.
Reece, D.
Anderson, L.D.
Saint-Martin, J.-R.
Jeha, J.
Joshi, A.A.
Chai, Y.
Li, L.
Peddagali, V.
Arazy, M.
Shah, J.
Shacham, S.
Kauffman, M.G.
Dimopoulos, M.A.
Richardson, P.G.
Delimpasi, S. |
Issue Date: | 2020 |
Source: | The Lancet, 2020 |
Journal Title: | The Lancet |
DOI: | 10.1016/S0140-6736(20)32292-3 |
metadata.dc.rights.holder: | Craig Wallington-Gates |
Type: | Article |
| Appears in Sites: | Sunshine Coast HHS Publications
|
